Biosimilars Books Drug Development 
European Pharmaceutical Review
OCTOBER 19, 2022
1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. Biopharmaceutical Research & Development: The Process Behind New Medicines. 2022;12(7):3049-3062.
pharmaphorum
JUNE 24, 2021
The original formulation has started to lose patent protection however, and a gaggle of drug developers – including Samsung Bioepis/Biogen, Hospira and Formycon/Bioeq – are already preparing to enter the US market with lower-cost biosimilars , with the first rivals expected to launch before year-end. billion in 2020 revenues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
FEBRUARY 27, 2023
As a renowned chemist, Dr. Senanayake discussed the need to adopt green chemistry in the process of drug development for cost reduction, timely innovation, and generating less waste than the standard process. To provide the audience with an Indian viewpoint, the presenters pointed out the country's requirements for biosimilar PV.
Express Pharma
JANUARY 1, 2025
It has a strong presence across various modalities, such as RNAi, ADC, peptides, lipids and oligonucleotides, and manufacturing techniques, such as flow chemistry, enzymatic processes, biocatalysis and fermentation, offering a broad range of technology capabilities for drug development. Its revenue from operations increased by 34.3
FDA Law Blog: Biosimilars
DECEMBER 6, 2024
As much of the content of this draft guidance for cellular and gene therapy (CGT) products is articulated elsewhere, this document serves as a one-stop shop or Cliffs Notes for the numerous guidance documents now covering CGT product development.
Expert insights. Personalized for you.
96 
Let's personalize your content